An article over at globenewswire.com, recounts the findings presented at the recent 2024 American Association for Cancer Research (AACR) Annual Meeting. One of the presentations was of results from a phase 1 clinical trial for Syncromune Inc.’s SYNC-T™ personalized in situ therapy for solid tumor cancers. SYNC-T was evaluated in people living with metastatic-castration resistant prostate cancer and produced an 85% overall response rate.
About SYNC-T and SV-102
SYNC-T is a novel treatment approach that combines intratumoral immunotherapy and partial tumor lysis. The procedure begins with a technique called lysis, which involves freezing a portion of the cancer tumor. This is believed to activate the immune system and release signals specific to cancer. Then, a multi-target drug with a fixed dose designated SV-102 is administered directly to the tumor. Overall, this approach is intended to stimulate the immune system and shut down any defenses from the cancer tumor that suppress the immune response. This direct approach also allows for a lower dose of drugs to be used versus systemic infusion, which should hopefully reduce the risk of adverse effects.
The Trial So Far
The trial included a total of 15 patients, and many of them had experienced failure from prior therapies and also presented with diffuse metastases in their bones. These patients received the treatment every four weeks and were treated up to twelve times. Response was evaluated at eight-week intervals. Five patients saw a complete response and six saw a partial response from a total of 13 patients that were deemed evaluable.
This trial is ongoing and so far, there haven’t been any major safety concerns. The full results are anticipated in the latter half of 2024.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. WHATNEXT and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
About Prostate Cancer
Prostate cancer occurs in the prostate gland, part of the male reproductive system that is positioned beneath the bladder. Risk factors for prostate cancer include old age, a family history of the disease, and being of African ancestry. Tumors can appear on the prostate as cells accumulate DNA mutations, but most do not become cancerous. In early stages, prostate cancer doesn’t cause symptoms, but as the disease progresses, difficulty urinating, erectile dysfunction, and bloody urine or semen can appear. Fatigue, bone or back pain, or unexpected weight loss are signs of metastatic disease. Treatment for prostate cancer can vary widely depending on risk and severity of the individual case. Options can include surgical removal of the prostate, hormone therapy, or radiation therapy. Chemotherapy is often used when the disease has spread. Due to screening programs, prostate cancer is often detected at an early stage, and in these cases, patients can have relatively long survival times after diagnosis. To learn more about prostate cancer, click here.
clinical trial metastatic castration-resistant prostate cancer news prostate cancer research treatment
Last modified: May 3, 2024
